Search the Newsreel

Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open

Arbutus Biopharma (ABUS) recently became profitable, with a significant surge in revenue and net income in Q2 2026, leading to a low trailing P/E of 5.6x. Despite this financial improvement, the stock has seen a muted market reaction and recent declines, suggesting investors are …

Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing

Morgan Stanley and Morgan Stanley Investment Management Inc. have disclosed significant beneficial ownership in Arbutus Biopharma Corp (ABUS) common shares through a Schedule 13G/A filing. As of June 30, 2026, Morgan Stanley reporting units beneficially own 8.8% of Arbutus Biopharma's common shares, while Morgan …

Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS) reported a quarterly loss of $0.03 per share, missing analyst expectations by $0.01. Despite the earnings miss, the company's revenue of $1.01 million surpassed the consensus estimate of $0.70 million. Following the announcement, ABUS shares declined by 3.0% to $4.53, while …

Arbutus Biopharma earnings matched, revenue topped estimates

Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact

Arbutus Biopharma Corporation reported its Q2 2026 financial results, showcasing a significant net income of $164,552 thousand for the six months ending June 30, 2026, primarily due to $179,373 thousand in license revenue from Genevant. This marks a substantial improvement from a net loss …

What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings

Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary

Arbutus Biopharma Corp reported its Q2 2026 results with revenue of $1.01M and a net loss of ($5.14M), a significant decrease from the prior year's $10.74M revenue and $2.52M net income. The diluted EPS was ($0.03) compared to $0.01 a year earlier. Key business …

Earnings Flash (ABUS) Arbutus Biopharma Posts Q2 Loss $0.03 a Share, vs. FactSet Est of $0.02 Loss

Arbutus: Q2 Earnings Snapshot

Arbutus Biopharma (ABUS) swings to $164.6M H1 profit on $178.4M Moderna payout

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expects to return up to approximately $230M in capital to Arbutus …

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - Should You Sell?

Arbutus Biopharma (NASDAQ:ABUS) shares have moved above their 200-day moving average, reaching $4.67 before closing at $4.59. The company's financial performance includes a quarterly EPS of $0.87 and $179.13 million in revenue, while institutional investors collectively hold 43.79% of its shares. Analyst sentiment is …

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with …

Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Arbutus Biopharma Corp (ABUS), highlighting its current earnings forecast score of 9.00 and an average price target of $5.00 from 2 analysts, who recommend a "Strong Buy". It also details expected revenue for the next quarter and …

Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Arbutus Biopharma Corp (ABUS), detailing its current risk score of 5.75 and ranking within the Biotechnology & Medical Research industry. It highlights the company's beta value of 0.63, indicating lower volatility compared to the S&P 500 index. …

Arbutus Biopharma Corp (ABUS) Institutional Confidence

The institutional confidence score for Arbutus Biopharma Corp (ABUS) is 5.00, placing it 132nd within the Biotechnology & Medical Research industry. Institutional shareholding increased by 3.63% quarter-over-quarter, reaching 65.56%. Roivant Sciences Ltd. is the largest institutional shareholder with 38.85M shares, while Morgan Stanley Investment …

Arbutus Biopharma (ABUS) Expected to Post Earnings on Wednesday

Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Arbutus Biopharma Corp (ABUS), noting its current valuation score of 8.62, which ranks it 106 out of 384 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at 5.17, significantly above its recent low …

ABUS|Arbutus Biopharma Corp|Price:4.280|Chg%:-0.130

TradingKey provides a comprehensive stock analysis of Arbutus Biopharma Corp (ABUS), highlighting its strong fundamentals and high growth potential despite a weak stock market performance. The company's valuation is considered fair, ranking 35th in its industry, with high institutional ownership. Analysts have given it …

Arbutus Biopharma Corporation $ABUS Shares Acquired by Rubric Capital Management LP

Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis

Arbutus Biopharma Corp (ABUS) has a strong financial health score of 8.63, ranking 37 out of 386 in the Biotechnology & Medical Research industry, indicating robust financial status and high operating efficiency. The company reported a significant year-over-year revenue increase of 10054.54% to 179.13M, …

Arbutus Biopharma Corp (ABUS) Cash Flow

The article provides a detailed quarterly and annual cash flow statement for Arbutus Biopharma Corp (ABUS), enabling evaluation of its financial soundness. It highlights current operating cash flow at -39.64M in fiscal 2025, which increased by 38.88% year-over-year, and details changes in investing and …

Arbutus Biopharma Corp (ABUS) Income Statement

This article provides the quarterly and annual income statements for Arbutus Biopharma Corp (ABUS), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes an FAQ section explaining how to read the income statement, distinguishing …

Arbutus Biopharma Corporation Revenue Breakdown – NASDAQ:ABUS

Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Arbutus Biopharma Corp (ABUS), focusing on its support and resistance levels, key indicators, and moving averages. As of July 24, 2026, the stock's price momentum score is 4.10, and it is trading between a resistance level of …

Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Arbutus Biopharma Corp (ABUS), listing its major shareholders and their proportions, including Roivant Sciences Ltd. and Morgan Stanley Investment Management Inc. It also categorizes shareholders by type and provides a historical overview of institutional holdings, showing changes …

Arbutus Plans $230M Buyback as Patent Fight Expands

Arbutus Biopharma Corp. plans to return up to $230 million to shareholders, partially funded by a $178 million settlement from Moderna related to lipid nanoparticle patent infringement. This shareholder return is expected to begin in Q3 2026, pending board approval and receipt of a …

Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNTech Over Patent Dispute

Arbutus Biopharma (ABUS) and Genevant Sciences have initiated three international lawsuits against Pfizer and BioNTech, alleging patent infringements related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a prior U.S. dispute and a $178 million settlement with Moderna. Despite strong financial stability …

Arbutus (ABUS) Secures $178 Million Settlement with Moderna

Arbutus Biopharma Corp (ABUS) has secured a $178 million settlement with Moderna to resolve patent infringement disputes related to Moderna’s COVID-19 vaccines. This payment will bolster Arbutus's cash reserves and allow it to focus on its core business of developing therapeutics for infectious diseases. …

Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return

Arbutus Biopharma and its licensee Genevant have filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their lipid nanoparticle technology, seeking monetary damages and injunctions. This follows Arbutus receiving approximately $178 million from Moderna to settle a similar patent dispute. …

Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback

Arbutus Biopharma received approximately $178 million from a settlement with Moderna regarding mRNA patent disputes and may receive up to an additional $1.3 billion. The company also announced plans to return up to $230 million to shareholders through common share repurchases, contingent on board …

Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders

Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their innovative LNP technology used in COVID-19 vaccines. Concurrently, Arbutus announced the receipt of approximately $178 million from Moderna as part of a previous …